261 related articles for article (PubMed ID: 30327940)
1. Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma.
Witte HM; Riecke A; Mayer T; Bartscht T; Rades D; Lehnert H; Merz H; Fetscher S; Biersack H; Gebauer N
J Cancer Res Clin Oncol; 2019 Jan; 145(1):129-136. PubMed ID: 30327940
[TBL] [Abstract][Full Text] [Related]
2. Low-dose trofosfamide plus rituximab is an effective and safe treatment for diffuse large B-cell lymphoma of the elderly: a single center experience.
Schelker RC; Herr W; Reichle A; Vogelhuber M
BMC Cancer; 2018 Oct; 18(1):1000. PubMed ID: 30340554
[TBL] [Abstract][Full Text] [Related]
3. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Laribi K; Denizon N; Bolle D; Truong C; Besançon A; Sandrini J; Anghel A; Farhi J; Ghnaya H; Baugier de Materre A
Ann Hematol; 2016 Oct; 95(10):1705-14. PubMed ID: 27485454
[TBL] [Abstract][Full Text] [Related]
4. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
[TBL] [Abstract][Full Text] [Related]
5. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
6. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
7. Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era.
Katoh D; Ochi Y; Yabushita T; Ono Y; Hiramoto N; Yoshioka S; Yonetani N; Matsushita A; Hashimoto H; Kaji S; Imai Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e91-e97. PubMed ID: 28918104
[TBL] [Abstract][Full Text] [Related]
8. Reduced-dose ICE chemotherapy ± rituximab is a safe and effective salvage therapy for fit elderly patients with diffuse large B-cell lymphoma.
Sarid N; Joffe E; Gibstein L; Avivi I; Polliack A; Perry C; Herishanu Y
Leuk Lymphoma; 2016 Jul; 57(7):1633-9. PubMed ID: 26643787
[TBL] [Abstract][Full Text] [Related]
9. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
[TBL] [Abstract][Full Text] [Related]
10. Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the
Storti S; Spina M; Pesce EA; Salvi F; Merli M; Ruffini A; Cabras G; Chiappella A; Angelucci E; Fabbri A; Liberati AM; Tani M; Musuraca G; Molinari A; Petrilli MP; Palladino C; Ciancia R; Ferrario A; Gasbarrino C; Monaco F; Fraticelli V; De Vellis A; Merli F; Luminari S
Haematologica; 2018 Aug; 103(8):1345-1350. PubMed ID: 29748444
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.
Arcari A; Chiappella A; Spina M; Zanlari L; Bernuzzi P; Valenti V; Tani M; Marasca R; Cabras MG; Zambello R; Santagostino A; Ilariucci F; Carli G; Musto P; Savini P; Marino D; Ghio F; Gentile M; Cox MC; Vallisa D
Leuk Lymphoma; 2016 Aug; 57(8):1823-30. PubMed ID: 26666433
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
13. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Park SI; Grover NS; Olajide O; Asch AS; Wall JG; Richards KL; Sobol AL; Deal AM; Ivanova A; Foster MC; Muss HB; Shea TC
Br J Haematol; 2016 Oct; 175(2):281-289. PubMed ID: 27448091
[TBL] [Abstract][Full Text] [Related]
15. Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose chemotherapy.
Andersson PO; Braide I; Nilsson-Ehle H
Leuk Lymphoma; 2002 Dec; 43(12):2351-3. PubMed ID: 12613523
[TBL] [Abstract][Full Text] [Related]
16. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL).
Jung SH; Lee JJ; Kim WS; Lee WS; Do YR; Oh SY; Kim MK; Mun YC; Shin HJ; Kwak JY; Kang HJ; Won JH; Kwon JH; Park E; Suh C; Yang DH
Eur J Haematol; 2015 Jun; 94(6):504-10. PubMed ID: 25288018
[TBL] [Abstract][Full Text] [Related]
17. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
18. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial.
Fayad L; Ansell SM; Advani R; Coiffier B; Stuart R; Bartlett NL; Forero-Torres A; Kuliczkowski K; Belada D; Ng E; Drachman JG
Leuk Lymphoma; 2015; 56(9):2569-78. PubMed ID: 25651427
[TBL] [Abstract][Full Text] [Related]
19. Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
Pfreundschuh M; Murawski N; Zeynalova S; Ziepert M; Loeffler M; Hänel M; Dierlamm J; Keller U; Dreyling M; Truemper L; Frickhofen N; Hünerlitürkoglu AN; Schmitz N; Pöschel V; Rixecker T; Berdel C; Rübe C; Held G; Zwick C
Br J Haematol; 2017 Nov; 179(3):410-420. PubMed ID: 28990173
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]